Are early relapses in advanced-stage ovarian cancer doomed to a poor prognosis?

Fabien Vidal, Paul Guerby, Mathieu Luyckx, Pascale Haddad, Eberhard Stoeckle, Philippe Morice, Eric Leblanc, Fabrice Lecuru, Emile Daraï, Jean Marc Classe, Christophe Pomel, Thomas Filleron, Gwenael Ferron, Denis Querleu, Arash Rafii Tabrizi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: Early recurrence (ER) after completion of therapeutic regimen in advanced-stage ovarian cancer is a challenging clinical situation. Patients are perceived as invariably having a poor prognosis.We investigated the possibility of defining different prognostic subgroups and the parameters implicated in prognosis of ER patients. Study Design: We analyzed a multi-centric database of 527 FIGO stage IIIC and IV ovarian cancer patients. We defined patients relapsing within 12 months as ER and investigated using Cox logistic regression the prognostic factors in ER group. We subsequently divided ER patients into good and poor prognosis groups according to a lower or higher overall survival (OS) at 12 months after relapse and determined parameters associated to poor prognosis. Results: The median follow up was 49 months. One hundred and thirty eight patients recurred within 12 months. OS and Disease Free Survival (DFS) were 24.6 and 8.6 months, respectively, in this group of patients. Among the ER patients, 73 had a poor prognosis with an OS after relapse below 12 months (mean OS = 5.2 months) and 65 survived after one year (mean OS = 26.9 months). Residual disease (RD) after debulking surgery and mucinous histological subtype negatively impacted prognosis (HR = 1.758, p = 0.017 and HR = 8.641, p = 0.001 respectively). The relative risk of death within 12 months following relapse in ER patients was 1.61 according to RD status. However, RD did not affect DFS (HR = 0.889, p = 0.5). Conclusion: ER in advanced-stage ovarian cancer does not inevitably portend a short-term poor prognosis. RD status after initial cytoreduction strongly modulates OS, that gives additional support to the concept of maximum surgical effort even in patients who will experience early recurrence. The heterogeneity in outcomes within the ER group suggests a role for tumor biology in addition to classical clinical parameters.

Original languageEnglish
Article numbere0147787
JournalPLoS One
Volume11
Issue number1
DOIs
Publication statusPublished - 1 Jan 2016

Fingerprint

ovarian neoplasms
relapse
Ovarian Neoplasms
prognosis
Recurrence
Survival
Surgery
Logistics
Tumors
Disease-Free Survival
relative risk
surgery
experimental design
death
Biological Sciences
therapeutics
neoplasms

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Vidal, F., Guerby, P., Luyckx, M., Haddad, P., Stoeckle, E., Morice, P., ... Tabrizi, A. R. (2016). Are early relapses in advanced-stage ovarian cancer doomed to a poor prognosis? PLoS One, 11(1), [e0147787]. https://doi.org/10.1371/journal.pone.0147787

Are early relapses in advanced-stage ovarian cancer doomed to a poor prognosis? / Vidal, Fabien; Guerby, Paul; Luyckx, Mathieu; Haddad, Pascale; Stoeckle, Eberhard; Morice, Philippe; Leblanc, Eric; Lecuru, Fabrice; Daraï, Emile; Classe, Jean Marc; Pomel, Christophe; Filleron, Thomas; Ferron, Gwenael; Querleu, Denis; Tabrizi, Arash Rafii.

In: PLoS One, Vol. 11, No. 1, e0147787, 01.01.2016.

Research output: Contribution to journalArticle

Vidal, F, Guerby, P, Luyckx, M, Haddad, P, Stoeckle, E, Morice, P, Leblanc, E, Lecuru, F, Daraï, E, Classe, JM, Pomel, C, Filleron, T, Ferron, G, Querleu, D & Tabrizi, AR 2016, 'Are early relapses in advanced-stage ovarian cancer doomed to a poor prognosis?', PLoS One, vol. 11, no. 1, e0147787. https://doi.org/10.1371/journal.pone.0147787
Vidal F, Guerby P, Luyckx M, Haddad P, Stoeckle E, Morice P et al. Are early relapses in advanced-stage ovarian cancer doomed to a poor prognosis? PLoS One. 2016 Jan 1;11(1). e0147787. https://doi.org/10.1371/journal.pone.0147787
Vidal, Fabien ; Guerby, Paul ; Luyckx, Mathieu ; Haddad, Pascale ; Stoeckle, Eberhard ; Morice, Philippe ; Leblanc, Eric ; Lecuru, Fabrice ; Daraï, Emile ; Classe, Jean Marc ; Pomel, Christophe ; Filleron, Thomas ; Ferron, Gwenael ; Querleu, Denis ; Tabrizi, Arash Rafii. / Are early relapses in advanced-stage ovarian cancer doomed to a poor prognosis?. In: PLoS One. 2016 ; Vol. 11, No. 1.
@article{5a63a45da1324cc79c892625e8a92fbb,
title = "Are early relapses in advanced-stage ovarian cancer doomed to a poor prognosis?",
abstract = "Objective: Early recurrence (ER) after completion of therapeutic regimen in advanced-stage ovarian cancer is a challenging clinical situation. Patients are perceived as invariably having a poor prognosis.We investigated the possibility of defining different prognostic subgroups and the parameters implicated in prognosis of ER patients. Study Design: We analyzed a multi-centric database of 527 FIGO stage IIIC and IV ovarian cancer patients. We defined patients relapsing within 12 months as ER and investigated using Cox logistic regression the prognostic factors in ER group. We subsequently divided ER patients into good and poor prognosis groups according to a lower or higher overall survival (OS) at 12 months after relapse and determined parameters associated to poor prognosis. Results: The median follow up was 49 months. One hundred and thirty eight patients recurred within 12 months. OS and Disease Free Survival (DFS) were 24.6 and 8.6 months, respectively, in this group of patients. Among the ER patients, 73 had a poor prognosis with an OS after relapse below 12 months (mean OS = 5.2 months) and 65 survived after one year (mean OS = 26.9 months). Residual disease (RD) after debulking surgery and mucinous histological subtype negatively impacted prognosis (HR = 1.758, p = 0.017 and HR = 8.641, p = 0.001 respectively). The relative risk of death within 12 months following relapse in ER patients was 1.61 according to RD status. However, RD did not affect DFS (HR = 0.889, p = 0.5). Conclusion: ER in advanced-stage ovarian cancer does not inevitably portend a short-term poor prognosis. RD status after initial cytoreduction strongly modulates OS, that gives additional support to the concept of maximum surgical effort even in patients who will experience early recurrence. The heterogeneity in outcomes within the ER group suggests a role for tumor biology in addition to classical clinical parameters.",
author = "Fabien Vidal and Paul Guerby and Mathieu Luyckx and Pascale Haddad and Eberhard Stoeckle and Philippe Morice and Eric Leblanc and Fabrice Lecuru and Emile Dara{\"i} and Classe, {Jean Marc} and Christophe Pomel and Thomas Filleron and Gwenael Ferron and Denis Querleu and Tabrizi, {Arash Rafii}",
year = "2016",
month = "1",
day = "1",
doi = "10.1371/journal.pone.0147787",
language = "English",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

TY - JOUR

T1 - Are early relapses in advanced-stage ovarian cancer doomed to a poor prognosis?

AU - Vidal, Fabien

AU - Guerby, Paul

AU - Luyckx, Mathieu

AU - Haddad, Pascale

AU - Stoeckle, Eberhard

AU - Morice, Philippe

AU - Leblanc, Eric

AU - Lecuru, Fabrice

AU - Daraï, Emile

AU - Classe, Jean Marc

AU - Pomel, Christophe

AU - Filleron, Thomas

AU - Ferron, Gwenael

AU - Querleu, Denis

AU - Tabrizi, Arash Rafii

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Objective: Early recurrence (ER) after completion of therapeutic regimen in advanced-stage ovarian cancer is a challenging clinical situation. Patients are perceived as invariably having a poor prognosis.We investigated the possibility of defining different prognostic subgroups and the parameters implicated in prognosis of ER patients. Study Design: We analyzed a multi-centric database of 527 FIGO stage IIIC and IV ovarian cancer patients. We defined patients relapsing within 12 months as ER and investigated using Cox logistic regression the prognostic factors in ER group. We subsequently divided ER patients into good and poor prognosis groups according to a lower or higher overall survival (OS) at 12 months after relapse and determined parameters associated to poor prognosis. Results: The median follow up was 49 months. One hundred and thirty eight patients recurred within 12 months. OS and Disease Free Survival (DFS) were 24.6 and 8.6 months, respectively, in this group of patients. Among the ER patients, 73 had a poor prognosis with an OS after relapse below 12 months (mean OS = 5.2 months) and 65 survived after one year (mean OS = 26.9 months). Residual disease (RD) after debulking surgery and mucinous histological subtype negatively impacted prognosis (HR = 1.758, p = 0.017 and HR = 8.641, p = 0.001 respectively). The relative risk of death within 12 months following relapse in ER patients was 1.61 according to RD status. However, RD did not affect DFS (HR = 0.889, p = 0.5). Conclusion: ER in advanced-stage ovarian cancer does not inevitably portend a short-term poor prognosis. RD status after initial cytoreduction strongly modulates OS, that gives additional support to the concept of maximum surgical effort even in patients who will experience early recurrence. The heterogeneity in outcomes within the ER group suggests a role for tumor biology in addition to classical clinical parameters.

AB - Objective: Early recurrence (ER) after completion of therapeutic regimen in advanced-stage ovarian cancer is a challenging clinical situation. Patients are perceived as invariably having a poor prognosis.We investigated the possibility of defining different prognostic subgroups and the parameters implicated in prognosis of ER patients. Study Design: We analyzed a multi-centric database of 527 FIGO stage IIIC and IV ovarian cancer patients. We defined patients relapsing within 12 months as ER and investigated using Cox logistic regression the prognostic factors in ER group. We subsequently divided ER patients into good and poor prognosis groups according to a lower or higher overall survival (OS) at 12 months after relapse and determined parameters associated to poor prognosis. Results: The median follow up was 49 months. One hundred and thirty eight patients recurred within 12 months. OS and Disease Free Survival (DFS) were 24.6 and 8.6 months, respectively, in this group of patients. Among the ER patients, 73 had a poor prognosis with an OS after relapse below 12 months (mean OS = 5.2 months) and 65 survived after one year (mean OS = 26.9 months). Residual disease (RD) after debulking surgery and mucinous histological subtype negatively impacted prognosis (HR = 1.758, p = 0.017 and HR = 8.641, p = 0.001 respectively). The relative risk of death within 12 months following relapse in ER patients was 1.61 according to RD status. However, RD did not affect DFS (HR = 0.889, p = 0.5). Conclusion: ER in advanced-stage ovarian cancer does not inevitably portend a short-term poor prognosis. RD status after initial cytoreduction strongly modulates OS, that gives additional support to the concept of maximum surgical effort even in patients who will experience early recurrence. The heterogeneity in outcomes within the ER group suggests a role for tumor biology in addition to classical clinical parameters.

UR - http://www.scopus.com/inward/record.url?scp=84958230893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958230893&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0147787

DO - 10.1371/journal.pone.0147787

M3 - Article

C2 - 26820579

AN - SCOPUS:84958230893

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 1

M1 - e0147787

ER -